XNASKRMD
Market cap181mUSD
Jan 10, Last price
3.96USD
1D
-1.00%
1Q
45.59%
Jan 2017
692.00%
Name
KORU Medical Systems Inc (Pre-Reincorp)
Chart & Performance
P/E
—
P/S
6.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.22%
Rev. gr., 5y
10.44%
Revenues
29m
+2.23%
Net income
-14m
L+58.65%
CFO
-5m
L-9.47%
Profile
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑02 | 2016‑02 | 2015‑02 | |
| Income | ||||||||||
Revenues | 28,518 2.23% | 27,896 18.76% | ||||||||
Cost of revenue | 17,552 | 17,483 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 10,966 | 10,413 | ||||||||
NOPBT Margin | 38.45% | 37.33% | ||||||||
Operating Taxes | 3,967 | (2,014) | ||||||||
Tax Rate | 36.18% | |||||||||
NOPAT | 6,999 | 12,427 | ||||||||
Net income | (13,741) 58.65% | (8,661) 89.82% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 446 | 407 | ||||||||
BB yield | -0.40% | -0.25% | ||||||||
| Debt | ||||||||||
Debt current | 792 | 877 | ||||||||
Long-term debt | 7,784 | 8,539 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (2,906) | (7,992) | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (4,893) | (5,405) | ||||||||
CAPEX | (783) | (2,802) | ||||||||
Cash from investing activities | (815) | (2,802) | ||||||||
Cash from financing activities | (219) | 279 | ||||||||
FCF | 8,521 | 7,442 | ||||||||
| Balance | ||||||||||
Cash | 11,482 | 17,408 | ||||||||
Long term investments | ||||||||||
Excess cash | 10,056 | 16,013 | ||||||||
Stockholders' equity | (22,821) | (9,083) | ||||||||
Invested Capital | 47,620 | 45,334 | ||||||||
ROIC | 15.06% | 29.99% | ||||||||
ROCE | 44.22% | 28.72% | ||||||||
| EV | ||||||||||
Common stock shares outstanding | 45,601 | 45,002 | ||||||||
Price | 2.46 -31.23% | 3.57 19.00% | ||||||||
Market cap | 111,951 -30.32% | 160,657 20.65% | ||||||||
EV | 109,045 | 152,666 | ||||||||
EBITDA | 11,836 | 11,000 | ||||||||
EV/EBITDA | 9.21 | 13.88 | ||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||